Ipca Laboratories Limited · NSE:IPCALAB
Ipca Laboratories — Investor Presentation (March 2025)
57 slides from Ipca Laboratories's investor presentation, March 2025
Slide 1: Corporate Presentation March 2025
£ipca A dose of life Ipca Laborato Corporate Presentation March 2025
Slide 2: About Us
About Us a Q@00€ Incorporation Consolidated Income Export to >16,000 | 70+ | FY202425 = JQO+ Employees . Maniecug bs years 39,032 cs | countries with sites labs ~ 0 ' USS1, 067 Mn onesie |
Slide 3: Our Values
Our Values a wae Qualiti Safeti Integriti | Digniti _— Responsibilit’ Adhere to Ensure safety Comply with Value Facilitate good standards comes first : ethics & standards people | business practices
Slide 4: Five Years' Highlights - Standalone
Five Years’ Highlights XN 6,749.21 %6,277.75 ($797.50) %5,925.81 ($757.82) ($738.69) %5,491.22 5,201.40 ($737.38) ($699.20) ace 3,570.05 ($465.59) 3,282.39 2,983.09 ($409.17) a) bier ($400.58) 333.94 oO -O- ~° %2,508.13 2,643.42 %2,707.70 2,808.96 ede ($336.80) (5329.52) ($326.86) ($331.91) —~CO- —O
Slide 5: Five Years' Highlights - Consolidated
Five Years’ Highlights Consolidated 9,032.39 10000 ($1,067.28) 9000 27,829.81 ($945.17) 8000 5,996.36 %6,369.94 7000 5,482.83 (8791.78) ($794.06) co0d G73) 4,894.16 5000 vale ($4578.30) 3,391.06 ($451.47) 2,818.61 i 4000 2,519.77 (5378-49) (5422.72) 4,138.23 4089.87 ($488.98) (5338.72) 3000 §-——0 20
Slide 6: Slide 6
Slide 7: Manufacturing Sites
Manufacturing Sites Formulations Kandla Baddi# Dehradun Jorethang (B-lactum) (2 facilities) (2 facilities) (2 facilities) Ratlam i i t New Delhi r a B capital i) B corporate Office Ghaziabad B® Formulations BW Biotech Overseas oo! if ’ Mumbai Pithampur — Piparia (Biotech) Pisgah Labs + , . ’ (North
Slide 8: Manufacturing Sites - Formulations
Athal (Dadra & Nagar Haveli) Ratlam (Madhya Pradesh) Kandla (Gujarat) Silvassa (Dadra & Nagar Haveli) Dehradun (Uttarakhand) Indore (SEZ) (Madhya Pradesh) Sikkim Tablets & Capsules Tablets, Liquids, Dry Syrup, Injectables & Ointments Betalactum-Tablets, Capsules & Dry Syrups Tablets & Capsules Table
Slide 9: Manufacturing Sites - Active Pharmaceutical Ingredients
Manufacturing Sites < Active naceutical Ingredients hace : “
Slide 10: Manufacturing Sites - APIs
Manufacturing Sites APIs Onyx Scientific (Sunderland, UK) Baroda Dewas Nandesari New Delhi Ratlam Ranu | B capital (R80) 7 BD Corporate Office apis B® reo Overseas ee ¥ Hingni Mumbai Pithampur* Mumbai Chh. Sambhajina ar + + (ran) Mahad a (Facts) et Pisgah Labs Ankleshwar — Tarapur Kolhapur* Vizag* N
Slide 11: Manufacturing Sites - APIs
Manufacturing Sites APIs [ Location | Inspections / Approvals by Agencies of ] e@ Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDOM, EU, India, Japan, Korea, Mexico, Russia, Slovenia, USA, WHO © Indore(Madhya Pradesh) nig B,WHO @ Dewas (Madhya Pradesh) India © Ankleshwar(Gujart) = nia Japan Me
Slide 12: Revenue Break-up 2023-24 & 24-25
pelenii e ‘Break -up 2023-24 & 20 24-25
Slide 13: Revenue Break-up
Revenue Break-up Standalone 2024-25 Total Total Revenue Exports Domestic 2024-25 2024-25 2024-25 2024-25 e e e Formulations: APIs Formulations e e e APIs Formulations : Export Domestic : APIs @ Formulations @ APIs @ Domestic @ Exports @ Formulations @ APIs @ Formulations @® APIs
Slide 14: Revenue Break-up
Revenue Break-up Standalone 2024-25 2023-24 TCs | Domestic | Exports | Total | Domestic | Exports | Total Growth | @ Branded Formulations 3,450.21 581.89 4,032.10 3,097.16 526.70 3,623.86 po Saco 489 133669 1,341.58 - 1,248.62 1,248.62 Tender Formulations © Total Formulations 3,455.10 1,918.58 5,373
Slide 15: Slide 15
Slide 16: FY 2024-25 vs FY 2023-24
FY 2024-25 FY 2023-24 Zs US$ Mn || Zs US$ Mn | % Growth © Total Income 6,749.21 797 6,277.75 758 8% e EBIDT 1,513.33 179 1,189.54 144 @ EBIDT% 22.66% - 19.29% - fF @ PBT 1,281.31 151 955.52 115 @ PAT 650.76 77 530.41 64 16 # After forex gain of $11.70 Crs as against ¥21.84 Crs for previous year.
Slide 17: Financials Standalone
Financials Standalone CO Profitability | FY 2024-25 FY 2023-24 PBIDT 19.29% PBIDT 22.66% @ PsioT GB Pst WB PAT @ PeioT WB Pst WB PAT
Slide 18: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 19: Financials
Financials Standalone FY 2024-25 FY 2023-24 @ Net Profit 22.7% 4.9%
Slide 20: Financials Consolidated
Financials Consolidated FY 2024-25 FY 2023-24 ZCrs US$ Mn | f ZCrs US$ Mn @ Total Income 9,032.39 1,067 7,829.81 e EBIDT 1,693.13 200 1,288.21 e@ EBIDT% 18.94% - 16.72% @ PBT* 1,336.19 158 842.67 @ PBT% 14.95% - 10.94% @ PAT* 737.68 87 547.35 e@ PAT% 8.25% - 7.10% # After forex gain of €33.01 Crs as
Slide 21: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 22: Financials
Financials Consolidated FY 2024-25 FY 2023-24 @ Net Profit 34.8% 9.2%
Slide 23: Contribution of Therapeutic Groups
Financials Standalone Contribution of Therapeutic Groups 2024-25 Domestic 2023-24 © Cardiovasculars®& Anti-Diabetics © Cardiovasculars®& Anti-Diabetics © Anti-Malarials © Anti-Malarials © NeuroPsychiatry © NeuroPsychiatry © Dermatology © Dermatology © Neutraceuticals e 1% 1% H © Neutraceuticals e -
Slide 24: Slide 24
Slide 25: Branded Formulations Domestic
Branded Formulations a Domestic . 22 Market leaders in Allndia Rank 1QVIA Therapy Focused Over 4000 Rheumatoid Arthritis 16" (MAT Dec’24) Marketing Divisions Wholesalers & Anti-malarials Gy @ 24 Depots & Field Strength 6 brands among ‘1 C&F agent (PSR / BA)-6689 top 300 brands (Zerodol-SP, Zerodol-P
Slide 26: Branded Formulations
Branded Formulations %3,097.16 ($374 Mn) %2,760.71 2,508.27 ($344Mn) ($337 Mn) %3,455.10 ($408.26MIn) 2021-22 2022-23 2023-24 2024-25 ~ / Domestic —O- 202425 2021-22 2022-23 2023-24 Figures in Crores. Sales
Slide 27: Branded Formulations Future Growth Drivers
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS. rail —® Strong brand building with focused promotion. te In-licensing / out-licensing to build business in the promoted therapy. Portfolio optimisation, strategies to
Slide 28: International Business
Internat tional ANN S Business _ ww
Slide 29: International Business
International Business a Registrations in 61 countries © Recognised _A Field-force to promote brands © Five Star Export gu in more than House 30 countries Products of the company 42% sales & Marketing offices in are now exported to over From exports ‘a 12 countries 100 countries across the globe
Slide 30: International Business
International Business (— > %2,808.96 3000 %2,508.13 %2,643.42 ee 2-808. $ ($337 Mn) (5330 Mn) 2500 2000 1500 1000 500 —O- wr425 | . 201-2 \ 2021-22 2022-23 2023-24 2024-25 ) 202273 Figures in Crores. Sales 30
Slide 31: Continent-wise Exports 2024-25
International Business a Continent-wise Exports 2024-25 (%Crs) Continent Formulations APIs | Total | % Contribution © Europe 525.00 281.11 806.11 29% © Africa 502.30 43.40 545.70 19% © Americas 267.43 268.57 536.00 19% © Asia 137.22 254.64 391.86 14% e ds 210.42 35.84 246.26 9% © Australasia 276.21
Slide 32: International Formulations
ee Interne a
Slide 33: International Formulations
International Formulations %1,775.32 ($214 Mn) 21,639.19 ($204 Mn) 1,486.74 ($200 Mn) %1,918.58 ($227 Mn) XX 2021-22 2022-23 2023-24 2024-25 ~ w —O— 2024-25 2021-22 2022-23 2023-24 Figures in Crores. Sales
Slide 34: International Branded Formulations
a International led Formulations =
Slide 35: International Branded Formulations
International Branded Formulations (— 581.89 >) 590 ($69 Mn) 570 550 526.70 530 504.79 ($64 Mn) an ($63 Mn) 490 470 450 %415.99 430 ($56 Mn) 410 390 370 350 —O- 2024-25 330 T T T 1 2021-22 L 2021-22 2022-23 2023-24 2024-25 O- 222 Figures in Crores. Sales 35
Slide 36: Future Growth Drivers
Future Growth Drivers ral International Branded Formulations Thrust on brand building in Pain, CVS, CNS, Anti-infective and Anti-malarial segments. Geographical expansion in covered countries through additional field force. Expansion in business lines - Institutions and Distributors. Introduction of
Slide 37: International Generics
pert tional Ane SS SSS
Slide 38: International Generics / Institution / Tender
International Generics / Institution / Tender >) Products Products Under tog 1,248.62 ane | Country | Registered Registration | ($151 Mn) fen United Kingdom 1200 1,070.75 1,134.40 58 3 (5144 Mn) (3141 Mn) /Europe 1000 Australia / RB 3 New Zealand 800 South Africa 53 10 600 United States / "7 7 400 C
Slide 39: International Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. al Formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements. Futur
Slide 40: International APIs
peat tional
Slide 41: International APIs
International APIs ~ 200 1,021.39 1,004.23 ($137 Mn) ($125 Mn) ¥932,38 $890.38 1000 (5113 Mn) ($105 Mn) 800 600 400 200 —O- 202425 A 2021-22 2022-23 L 2021-22 2022-23 2023-24 2024-25 y 2023-24 Figures in Crores. Sales 41
Slide 42: APIs - Drug Master Files
International APIs - Drug Master Files fl | DMF | Name of the API usrpa | Canada = wyo | 7aPa | pustralia | EQDM 1 1 Alendronate Sodium () c - v7) - Q@ 2 2 Allopurinol (7) @ = = CEP @ 3 3 Amlodipine Besylate () : - - - @ 4 Amlodipine Besylate (AK4 Process) - - - = ° g@ 4 5 Amodiaquine HCI = 2 @ - -
Slide 43: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 11 12 12 13 13 14 14 15 15 16 16 7 18 7 19 18 20 21 19 22 Name of the API Benzarone Benzbromarone Bisoprolol Fumarate Bupropion Hydrochloride Carvedilol Celecoxib Cetrizine Hydrochloride (CZ Process) Cetrizine Hydrochloride (CZ5 / CZ6 Process) Chloroquine Phosphate Chlorth
Slide 44: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 20 23 21 24 22 25 23 26 24 27 28 25 29 30 26 31 27 32 28 33 Name of the API Citalopram HBR Dihydroartemesinin Donepezil Hydrochloride Monohydrate Duolexitine Hydrochloride Entacapone Etodolac (ED6 Process) Etodolac (ED7 Process) Famotidine Famotidine (FM3 Process) Fenofibr
Slide 45: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Mar’25 (Based on DMFs Sr. No.) API | DMF Canada- Japan- . Sr. No.| Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM | x0 35 Furosemide ° — 2 ° CEP Ad 36 Furosemide (Veterinary) 38 Felodipine ce 40 Hydrochlorothiazide (Process |
Slide 46: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Mar’25 (Based on DMFs Sr. No.) API | DMF Canada- Japan- . Sr. No.| Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM | 46 Indapamide a 48 Losartan Potassium (LB3 Process) 40 49 Losartan Potassium (LB4 Process) - = 3 - - ° 50 Los
Slide 47: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 56 45 57 46 58 47 59 60 48 61 49 62 63 50 64 51 65 52 66 Name of the API Metformin HCL (ML Process) Metformin HCL (ML2 Process) Methylphenidate HCI Metoclopramide Base Metoclopramide HCI Metoclopramide HCl (M Process) Metoprolol Succinate Metoprolol Tartrate Metoprolol Tar
Slide 48: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 53 67 54 68 55 69 56 70 57 71 58 72 59 73 60 74 61 75 62 76 63 77 Name of the API Olanzapine Ondansetron Base Ondansetron Hydrochloride Paroxetine HCI Piperaquine Phosphate Primaquine Phosphate Proguanil Hydrochloride Propranolol HCI Pyrantel Embonate Pyrantel Pamoate Pyri
Slide 49: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 78 64 79 65 80 66 81 82 67 83 68 84 69 85 70 86 71 87 Name of the API Quetiapine Fumarate Quetiapine Fumarate (QT5 Process) Risendronate Sodium Hemi-Pentahydarate Risperidone Telmisartan Telmisartan (WT6 Process) Torsemide Tramadol Hydrochloride (YT3 Process) Trazodone Hyd
Slide 50: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Mar’25 (Based on DMFs Sr. No.) (SAR, SPME,| Name ofthe aP | uso | Canad wo Jamar | australia | E0DM | 2 88 Valsartan (VA6 Process) g - - - - Qe B 89 — Venlafexine Hydrochloride @ - = 3 - @ 7432 Warfarin Sodium - - - - CEP — Warfarin Sodium
Slide 51: International APIs Future Growth Drivers
International APIs -—® Consolidate API business of Sartans across the globe. Future Growth Drivers ‘—© Long term strategic tie-ups with major South American / European formulators. Leverage the customer base of more than 1000 customers spread across 90 _A countries is well laid down platform to intr
Slide 52: Slide 52
Slide 53: Research & Development
Research & Development APIs & Formulations ( ») Year | Xrs % to sales | 220 e071 5.50% 200 : 5.00% 2020-21 126.67 2.49% 161.50 uy 14646 15649 2.64% Ges 2021-22 141.46 2.63% 160) = 2.63% 2.71% 4.00% ao | <126.67 3.50% 2022-23 156.49 2.71% 120 3.00% a An 2023-24 161.50 2.64% 80 2.00% 2024-25 207.16 3.
Slide 54: Research & Development
Research & Development APIs & Formulations -—® Current scientist manpower of 625+. Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 264 patent applications filed. Biotech / fermentation
Slide 55: Overview of Advanced Biotech Lab
Overview of Advanced Biotech Lab Biosimilar R&D and Bio-manufacturing -—® Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable ofin-house development from “Clone to Commercialization” Single-use CGMP Bio-manufacturing Facility (DS+DP+0C) is being established and to be ready by
Slide 56: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines Molecules: Anti-cancer, Anti-inflammatory and Opthalmic mAbs Stage of Development [ Molecules - Se © 7 Monoclonal antibodies (mAbs) and One Non- Pre-clinical | Clinical Trials | MAA /Launch mAb Biosimilar at various stages of the development UK/HC/IN/EU © Target markets I
Slide 57: Slide 57
Ipca Laboratories — Investor Presentation (March 2025) on 6ix